Navidea Meets Guidance With 2015 Unaudited Lymphoseek® Sales of $10.2 Million
January 11 2016 - 6:45AM
Business Wire
- Provides Corporate Update in Shareholder
Letter Reviewing 2015 and Previewing 2016 -
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today reports
2015 preliminary unaudited Lymphoseek® (technetium Tc 99m
tilmanocept) injection sales of $10.2 million, achieving 2015
guidance. Total revenue, which will include license and grant
revenue, will be provided when the Company reports full-year end
results in early March.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160111005515/en/
The letter to shareholders is now available and may be accessed
at the following link, 2016 Shareholder Letter.
As a reminder, Rick Gonzalez, President and Chief Executive
Officer, will present at Biotech Showcase 2016, taking place
in San Francisco, CA, on Tuesday, January
12th at 2:30 PM PT (5:30 PM ET). The live
presentation will be available by webcast at the following link:
http://edge.media-server.com/m/p/6j593adk. An archived version of
the webcast will be available two hours following the presentation
and can be accessed within the Investors' section of the
Navidea website at www.navidea.com.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision immunodiagnostic agents and
immunotherapeutics. Navidea is developing multiple
precision-targeted products and platforms including Manocept™ and
NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and in Europe in November 2014. Navidea’s
strategy is to deliver superior growth and shareholder return by
bringing to market novel products and advancing the Company’s
pipeline through global partnering and commercialization efforts.
For more information, please visit www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act)
provides a safe harbor for forward-looking statements made by or on
behalf of the Company. Statements in this news release, which
relate to other than strictly historical facts, such as statements
about the Company’s plans and strategies, expectations for future
financial performance, new and existing products and technologies,
anticipated clinical and regulatory pathways, and markets for the
Company’s products are forward-looking statements within the
meaning of the Act. The words “believe,” “expect,” “anticipate,”
“estimate,” “project,” and similar expressions identify
forward-looking statements that speak only as of the date hereof.
Investors are cautioned that such statements involve risks and
uncertainties that could cause actual results to differ materially
from historical or anticipated results due to many factors
including, but not limited to, the Company’s continuing operating
losses, uncertainty of market acceptance of its products, reliance
on third party manufacturers, accumulated deficit, future capital
needs, uncertainty of capital funding, dependence on limited
product line and distribution channels, competition, limited
marketing and manufacturing experience, risks of development of new
products, regulatory risks and other risks detailed in the
Company’s most recent Annual Report on Form 10-K and other
Securities and Exchange Commission filings. The Company undertakes
no obligation to publicly update or revise any forward-looking
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160111005515/en/
Navidea BiopharmaceuticalsInvestorsTom Baker,
617-532-0624tbaker@navidea.comorMediaSharon Correia,
978-655-2686Associate Director, Corporate CommunicationsorDavid
Shull or Chris Hippolyte, 858-717-2310
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2024 to May 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From May 2023 to May 2024